Cryo-cell International Inc (CCEL)

$7.5

+0.13

(+1.76%)

Market is closed - opens 7 PM, 22 Apr 2024

Insights on Cryo-cell International Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 7.87M → 7.85M (in $), with an average decrease of 0.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -11.19M → 556.24K (in $), with an average increase of 2111.7% per quarter

Performance

  • $6.82
    $8.04
    $7.50
    downward going graph

    9.07%

    Downside

    Day's Volatility :15.15%

    Upside

    6.69%

    downward going graph
  • $3.67
    $8.15
    $7.50
    downward going graph

    51.07%

    Downside

    52 Weeks Volatility :54.97%

    Upside

    7.98%

    downward going graph

Returns

PeriodCryo-cell International IncIndex (Russel 2000)
3 Months
44.79%
0.0%
6 Months
65.2%
0.0%
1 Year
107.18%
-1.2%
3 Years
-35.34%
-19.2%

Highlights

Market Capitalization
60.8M
Book Value
- $1.25
Earnings Per Share (EPS)
-1.16
PEG Ratio
0.0
Wall Street Target Price
9.0
Profit Margin
-31.02%
Operating Margin TTM
10.39%
Return On Assets TTM
-0.93%
Return On Equity TTM
129.2%
Revenue TTM
31.4M
Revenue Per Share TTM
3.78
Quarterly Revenue Growth YOY
0.4%
Gross Profit TTM
21.5M
EBITDA
166.4K
Diluted Eps TTM
-1.16
Quarterly Earnings Growth YOY
-0.25
EPS Estimate Current Year
0.03
EPS Estimate Next Year
0.12
EPS Estimate Current Quarter
-0.02
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Cryo-cell International Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 20.0%

Current $7.50
Target $9.00

Company Financials

FY18Y/Y Change
Revenue
29.2M
↑ 15.1%
Net Income
-854.8K
↓ 136.92%
Net Profit Margin
-2.93%
↓ 12.05%
FY19Y/Y Change
Revenue
31.8M
↑ 8.89%
Net Income
2.3M
↓ 367.98%
Net Profit Margin
7.2%
↑ 10.13%
FY20Y/Y Change
Revenue
31.1M
↓ 2.1%
Net Income
3.6M
↑ 58.23%
Net Profit Margin
11.64%
↑ 4.44%
FY21Y/Y Change
Revenue
28.9M
↓ 7.26%
Net Income
2.1M
↓ 42.52%
Net Profit Margin
7.21%
↓ 4.43%
FY22Y/Y Change
Revenue
30.3M
↑ 5.03%
Net Income
2.8M
↑ 33.02%
Net Profit Margin
9.14%
↑ 1.93%
FY23Y/Y Change
Revenue
31.3M
↑ 3.32%
Net Income
-9.5M
↓ 443.57%
Net Profit Margin
-30.38%
↓ 39.52%
Q4 FY22Q/Q Change
Revenue
7.8M
↑ 1.08%
Net Income
837.8K
↑ 79.47%
Net Profit Margin
10.79%
↑ 4.71%
Q1 FY23Q/Q Change
Revenue
7.8M
↑ 0.78%
Net Income
766.8K
↓ 8.48%
Net Profit Margin
9.8%
↓ 0.99%
Q2 FY23Q/Q Change
Revenue
7.8M
↓ 0.66%
Net Income
221.0K
↓ 71.18%
Net Profit Margin
2.84%
↓ 6.96%
Q3 FY23Q/Q Change
Revenue
7.9M
↑ 1.25%
Net Income
680.6K
↑ 207.98%
Net Profit Margin
8.65%
↑ 5.81%
Q4 FY23Q/Q Change
Revenue
7.9M
↑ 0.09%
Net Income
-11.2M
↓ 1744.23%
Net Profit Margin
-142.06%
↓ 150.71%
Q1 FY24Q/Q Change
Revenue
7.9M
↓ 0.31%
Net Income
556.2K
↓ 104.97%
Net Profit Margin
7.08%
↑ 149.14%
FY18Y/Y Change
Total Assets
42.4M
↑ 77.29%
Total Liabilities
51.3M
↑ 40.88%
FY19Y/Y Change
Total Assets
42.9M
↑ 1.17%
Total Liabilities
49.8M
↓ 2.84%
FY20Y/Y Change
Total Assets
46.2M
↑ 7.73%
Total Liabilities
48.9M
↓ 1.95%
FY21Y/Y Change
Total Assets
60.7M
↑ 31.3%
Total Liabilities
56.5M
↑ 15.58%
FY22Y/Y Change
Total Assets
64.9M
↑ 6.97%
Total Liabilities
66.4M
↑ 17.59%
FY23Y/Y Change
Total Assets
61.2M
↓ 5.65%
Total Liabilities
72.3M
↑ 8.79%
Q4 FY22Q/Q Change
Total Assets
64.9M
↓ 2.81%
Total Liabilities
66.4M
↓ 3.96%
Q1 FY23Q/Q Change
Total Assets
66.1M
↑ 1.92%
Total Liabilities
66.8M
↑ 0.62%
Q2 FY23Q/Q Change
Total Assets
68.8M
↑ 3.97%
Total Liabilities
69.6M
↑ 4.18%
Q3 FY23Q/Q Change
Total Assets
69.8M
↑ 1.51%
Total Liabilities
69.8M
↑ 0.28%
Q4 FY23Q/Q Change
Total Assets
61.2M
↓ 12.29%
Total Liabilities
72.3M
↑ 3.49%
Q1 FY24Q/Q Change
Total Assets
61.7M
↑ 0.8%
Total Liabilities
72.0M
↓ 0.28%
FY18Y/Y Change
Operating Cash Flow
5.3M
↓ 6.73%
Investing Cash Flow
-11.3M
↓ 12228.36%
Financing Cash Flow
5.7M
↓ 288.33%
FY19Y/Y Change
Operating Cash Flow
6.3M
↑ 18.56%
Investing Cash Flow
-690.7K
↓ 93.88%
Financing Cash Flow
-5.1M
↓ 189.87%
FY20Y/Y Change
Operating Cash Flow
8.5M
↑ 33.9%
Investing Cash Flow
357.5K
↓ 151.76%
Financing Cash Flow
-5.0M
↓ 2.49%
FY21Y/Y Change
Operating Cash Flow
7.9M
↓ 6.38%
Investing Cash Flow
-7.0M
↓ 2044.47%
Financing Cash Flow
-3.1M
↓ 38.59%
FY22Y/Y Change
Operating Cash Flow
8.6M
↑ 8.16%
Investing Cash Flow
-15.3M
↑ 119.81%
Financing Cash Flow
147.9K
↓ 104.81%
Q4 FY22Q/Q Change
Operating Cash Flow
2.4M
↓ 9.64%
Investing Cash Flow
1.9M
↓ 117.06%
Financing Cash Flow
-5.6M
↓ 164.29%
Q1 FY23Q/Q Change
Operating Cash Flow
1.6M
↓ 32.34%
Investing Cash Flow
-1.2M
↓ 162.75%
Financing Cash Flow
-772.8K
↓ 86.11%
Q2 FY23Q/Q Change
Operating Cash Flow
2.0M
↑ 21.0%
Investing Cash Flow
-1.6M
↑ 31.04%
Financing Cash Flow
-663.2K
↓ 14.18%
Q3 FY23Q/Q Change
Operating Cash Flow
1.9M
↓ 2.35%
Investing Cash Flow
-3.4M
↑ 115.01%
Financing Cash Flow
903.9K
↓ 236.28%

Technicals Summary

Sell

Neutral

Buy

Cryo-cell International Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cryo-cell International Inc
Cryo-cell International Inc
23.36%
65.2%
107.18%
-35.34%
-35.34%
Fresenius Medical Care Ag
Fresenius Medical Care Ag
-0.61%
10.71%
-10.37%
-49.25%
-50.19%
Hca Holdings, Inc.
Hca Holdings, Inc.
-7.22%
26.53%
12.68%
58.14%
165.31%
Universal Health Services Inc.
Universal Health Services Inc.
-12.46%
26.3%
15.72%
8.69%
28.13%
Davita Healthcare Partners Inc.
Davita Healthcare Partners Inc.
-7.9%
64.89%
53.78%
13.92%
150.14%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cryo-cell International Inc
Cryo-cell International Inc
17.12
NA
0.0
0.03
1.29
-0.01
NA
-1.25
Fresenius Medical Care Ag
Fresenius Medical Care Ag
21.54
21.54
0.39
2.04
0.05
0.03
0.03
46.42
Hca Holdings, Inc.
Hca Holdings, Inc.
15.65
15.65
1.44
20.64
0.12
0.11
0.01
-6.68
Universal Health Services Inc.
Universal Health Services Inc.
15.39
15.39
1.87
13.45
0.12
0.05
0.01
91.53
Davita Healthcare Partners Inc.
Davita Healthcare Partners Inc.
17.0
17.0
1.16
9.01
0.39
0.06
NA
11.89
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cryo-cell International Inc
Cryo-cell International Inc
Buy
$60.8M
-35.34%
17.12
-31.02%
Fresenius Medical Care Ag
Fresenius Medical Care Ag
Hold
$11.4B
-50.19%
21.54
2.57%
Hca Holdings, Inc.
Hca Holdings, Inc.
Buy
$78.6B
165.31%
15.65
8.07%
Universal Health Services Inc.
Universal Health Services Inc.
Hold
$10.6B
28.13%
15.39
5.03%
Davita Healthcare Partners Inc.
Davita Healthcare Partners Inc.
Hold
$11.0B
150.14%
17.0
5.7%

Institutional Holdings

  • Hamilton Lane Advisors LLC

    4.94%
  • SFI Advisors, LLC

    1.99%
  • MASSMUTUAL TRUST CO FSB/ADV

    1.38%
  • Vanguard Group Inc

    1.10%
  • Northern Trust Corp

    0.32%
  • Geode Capital Management, LLC

    0.25%

Company Information

founded in 1989, cryo-cell is the oldest cord blood bank and was the first cord blood bank to separate and store stem cells in 1992. today, the company has over 270,000 clients worldwide. since inception, 100% of our clients’ specimens have been successfully viable upon thaw. our services include umbilical cord blood, cord tissue and menstrual stem cell banking. cryo-cell operates its own state-of-the-art processing, testing and cryopreservation operation. we are in complete control of every step, ensuring the highest quality available today.

Organization
Cryo-cell International Inc
Employees
82
CEO
Mr. David I. Portnoy
Industry
Services to the Health Industry

FAQs